Dr. Igor Fisch, CEO of Selexis SA, a drug discovery and cell-line development services company, speaks to Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio, about Selexis' focus on biologics and its business model centered on licensing deals. During BIO-Europe Spring 2016 in Stockholm, Sweden, the pair discuss Selexis' unique selling point, how the company works with academia to produce innovative technology, and how the growing biosimilars market might affect the business in coming years.
Want to elevate your brand and connect with potential partners? The Cell & Gene Exchange brings together leaders from patient advocacy groups, industry, academia and government to network, exchange ideas and explore partnership opportunities. Learn more here.